Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
Severe asthma greatly affects patients’ quality of life. Major advances have occurred in the management of severe eosinophilic asthma the past few years due to the new targeted biological therapies. There are three anti-IL-5 mAbs, mepolizumab, reslizumab and benralizumab. Despite the different mecha...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/8/3969 |
| _version_ | 1797537985062764544 |
|---|---|
| author | Agamemnon Bakakos Nikoleta Rovina Petros Bakakos |
| author_facet | Agamemnon Bakakos Nikoleta Rovina Petros Bakakos |
| author_sort | Agamemnon Bakakos |
| collection | DOAJ |
| description | Severe asthma greatly affects patients’ quality of life. Major advances have occurred in the management of severe eosinophilic asthma the past few years due to the new targeted biological therapies. There are three anti-IL-5 mAbs, mepolizumab, reslizumab and benralizumab. Despite the different mechanism of blocking IL-5 the clinical effects are quite similar as randomized controlled trials and real-life studies have shown. Moreover, there are reports of responding to one after failing to respond to another anti-IL-5 therapy. Accordingly, it is challenging to explore the possible differences in the response to anti-IL-5 treatments. This might help us not only understand possible mechanisms that contribute to the resistance to treatment in this particular asthma endotype, but also to phenotype within severe eosinophilic asthma in order to treat our patients more efficiently. |
| first_indexed | 2024-03-10T12:24:00Z |
| format | Article |
| id | doaj.art-56c5ea15ef9945e7bce6b58b59692c49 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T12:24:00Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-56c5ea15ef9945e7bce6b58b59692c492023-11-21T15:11:41ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-04-01228396910.3390/ijms22083969Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R TherapyAgamemnon Bakakos0Nikoleta Rovina1Petros Bakakos2Department of Respiratory Medicine, National and Kapodistrian University of Athens, 157 72 Athens, GreeceDepartment of Respiratory Medicine, National and Kapodistrian University of Athens, 157 72 Athens, GreeceDepartment of Respiratory Medicine, National and Kapodistrian University of Athens, 157 72 Athens, GreeceSevere asthma greatly affects patients’ quality of life. Major advances have occurred in the management of severe eosinophilic asthma the past few years due to the new targeted biological therapies. There are three anti-IL-5 mAbs, mepolizumab, reslizumab and benralizumab. Despite the different mechanism of blocking IL-5 the clinical effects are quite similar as randomized controlled trials and real-life studies have shown. Moreover, there are reports of responding to one after failing to respond to another anti-IL-5 therapy. Accordingly, it is challenging to explore the possible differences in the response to anti-IL-5 treatments. This might help us not only understand possible mechanisms that contribute to the resistance to treatment in this particular asthma endotype, but also to phenotype within severe eosinophilic asthma in order to treat our patients more efficiently.https://www.mdpi.com/1422-0067/22/8/3969asthmasevere eosinophilic asthmaanti-IL-5anti-IL-5Rmepolizumabbenralizumab |
| spellingShingle | Agamemnon Bakakos Nikoleta Rovina Petros Bakakos Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy International Journal of Molecular Sciences asthma severe eosinophilic asthma anti-IL-5 anti-IL-5R mepolizumab benralizumab |
| title | Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy |
| title_full | Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy |
| title_fullStr | Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy |
| title_full_unstemmed | Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy |
| title_short | Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy |
| title_sort | treatment challenges in severe eosinophilic asthma differential response to anti il 5 and anti il 5r therapy |
| topic | asthma severe eosinophilic asthma anti-IL-5 anti-IL-5R mepolizumab benralizumab |
| url | https://www.mdpi.com/1422-0067/22/8/3969 |
| work_keys_str_mv | AT agamemnonbakakos treatmentchallengesinsevereeosinophilicasthmadifferentialresponsetoantiil5andantiil5rtherapy AT nikoletarovina treatmentchallengesinsevereeosinophilicasthmadifferentialresponsetoantiil5andantiil5rtherapy AT petrosbakakos treatmentchallengesinsevereeosinophilicasthmadifferentialresponsetoantiil5andantiil5rtherapy |